期刊文献+

非甾体抗炎药心血管不良反应证据评估和处理程序分析 被引量:2

下载PDF
导出
摘要 目的:介绍和分析FDA处理非甾体抗炎药心血管不良事件的程序、方法和理念。方法:叙述性综述和评论。结果:在发现和确认心血管不良作用过程中,观察性或流行病学研究的作用有限,而随机对照临床试验具有特殊的作用。对复杂的心血管不良事件问题的处理环节包括专家咨询会议和有关技术部门提出“处理意见书”。专家咨询会议采用“诉辩”陈述、专家表述意见或表决的方式进行证据解读、利弊评估和措施建议。在咨询会议的基础上。“处理意见书”提出完整的具体的处理建议,并说明依据。整个过程中体现出,有关方面人员参与,程序规范和内容公开,合理推论、知情通告和举证倒置的决策理念。结论:充分了解各种研究方法的长处和缺点,结合具体不良事件的特点,合理地应用和采信。内容公开和程序规范是公正地解读和处理复杂问题的基础和保证。
出处 《药物流行病学杂志》 CAS 2005年第4期201-204,共4页 Chinese Journal of Pharmacoepidemiology
  • 相关文献

参考文献13

  • 1WHO. Cyclo-oxygennase-2 inhibitors[J]. WHO Pharmaceuticals Newsletter, 2004, (5) :7-8
  • 2Bonnel R, Karwoski CB. OPDRA postmarketing safety review [ EB/OL ]. www. fda. gov/ohrms/dockets/ac/01/briefing/3677 b1-1 1-thrombo. pdf , 2001-2/2004-12
  • 3SFDA.国家食品药品监督管理局密切关注非甾体抗炎药物的安全性问题[EB/OL].www.sfda.gov.cn,2005-04-12/2005-05.
  • 4Kweder S. Statement of Sandra Kweder, Deputy Director,Office of NDCDER, FDA [ EB/OL ]. Www. Fda. Gov/ola/2004 /vioxx1 118. Html , 2004-11-18/2004-12
  • 5Juni P, Nartey L, Reihenback S, et al. Rick of cardiovascular events and rofecoxib: cumulative meta-analysis [ J ].Lancet, 2004,364:2021-2029
  • 6Merck &. Co. , Inc. Merck announces voluntary worldwide withdrawal of VIOXX[ EB/OL]. www. merck. com ,2004-09/2004-12
  • 7默沙东公司.美国默克公司宣布主动自全球市场撤回万洛[EB/OL].www. msdchina. com. cn/vioxx/vioxx-1. html,2004-10/2004-12.
  • 8Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis [ J ]. N Engl J Med, 2000,343; 1520-1528
  • 9FDA. FDA alert for healthcare providers [ EB/OL ]. www.fda. gov/cder/drug/infosheets/HCP/Naproxen-hcp. pdf ,2004-12-23/2004-12
  • 10Jenkins JK, Seligman PJ (FDA). Memorandum--Analysis and recommendations for Agency action regarding NSAIDs and cardiovascular risk [ EB/OL ]. www. fda. gov/cder/drug/infopage/COX2/NSAIDdecisionMemo. pdf, 2005-04 -06/2005 -05

二级参考文献11

  • 1FDA announces a series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs). www. fda.gov/bbs/topics/news/2005/NEW01171. html , 2005-04-07/2005 -05.
  • 2COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). www. fda. gov/cder/drug/infopage/ COX2/ default. htm ,2005-04-07/2005-05.
  • 3Questions and Answers: FDA Regulatory Actions for the COX-2 Selective and Non-Selective Non-Steroidal Anti-inflammatory drugs ( NSAIDs ) . www. fda. gov/cder/drug/infopage/ COX2/ CO X2qa. htm ,2005-04-07/2005-05.
  • 4FDA Public Health Advisory: FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs(NSAIDs ). www. fda. gov/cder/drug/advisory/COX2. htm,2005 -04-07/2005 -05.
  • 5.国家食品药品监督管理局密切关注非甾体类抗炎药物的安全性问题[EB/OL].http://www.sfda.gov.cn/cmsweb/webportal/W1/search. html,2005-04-12/2005-05.
  • 6European Medicines Agency announces regulatory action on COX-2 inhibitors. http ://www. emea. eu. int/htms/hotpress/d6275705. htm, 2005-04-17/2005-05.
  • 7European Medicines Agency statement on the suspension of use of Bextra. http://www. emea. eu. int/htms/hotpress/h12163705. htm, 2005-04-12/2005-05.
  • 8Media Releases Stringent Conditions for COX-2 Inhibitors.http ://www. medsafe. govt. hz/hot/media/2005/COX2April05. htm, 2005-04 -29/2005-05.
  • 9Health Canada has asked Pfizer to suspend sales of its drug BextraTM and informs canadians of new restrictions on the use of Celebrex (R). http://www. hc-sc. gc. ca/english/media/releases/2005 / statement_drug_safety. html , 2005-04-07/2005-05.
  • 10Expanded information on Cox-2 inhibitors for doctors and pharmacists (amended * ). http://www. tga. gov. au/media/2005/050214_cox2. htm#pdf , 2005-04-14/2005-05.

共引文献9

同被引文献24

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部